The aim of this study was to assess whether the use of 24-h blood pressure (BP) measurement in the management of antihypertensive therapy improves BP in patients with sustained hypertension. Patients with sustained hypertension (office BP X140/90 mm Hg, and 24-h systolic BP X130/80 mm Hg) were randomly assigned to a strategy using 24-h BP to manage antihypertensive treatment (target o130/80 mm Hg) or to a standard strategy using office BP (target o140/90 mm Hg). The primary end point was change in 24-h systolic BP at 1 year of follow-up. We included 136 patients in the primary analysis. After 1 year of follow-up, the change in 24-h systolic BP was significantly greater in the ambulatory BP group compared with the office BP group (mean difference (95% confidence interval) À3.6 (À7.0, À0.3), P ¼ 0.03). Intentionto-treat analysis revealed essentially unchanged results.
Introduction
On the basis of numerous large-scale randomized trials, current guidelines recommend the use of office blood pressure measurement for the initiation and management of blood pressure-lowering therapy in patients with hypertension.
1,2 Although availability and simplicity of the technique are major strengths of this approach, there are also several important limitations. First, because of the elevated variability of office blood pressure, less than 50% of subjects are within 10 mm Hg of systolic blood pressure after repeated office blood pressure measurement. 3 Second, office blood pressure is taken in an artificial environment and does not necessarily reflect an individual's blood pressure outside the physician's office, such that white coat hypertension is diagnosed in around 20% of individuals with office hypertension. [4] [5] [6] Ambulatory blood pressure measurement overcomes most of these limitations. By recording multiple blood pressure measurements outside the physician's office, this method substantially reduces intra-individual variability and is a better correlate of the true blood pressure burden. 3, 7 Consequently, at least 80% of participants were within 10 mm Hg of systolic blood pressure and 5 mm Hg of diastolic blood pressure after a repeated 24-h blood pressure measurement. 3 Accordingly, ambulatory blood pressure measurement is a better predictor of cardiovascular morbidity and mortality than office blood pressure. [8] [9] [10] [11] [12] [13] [14] [15] Randomized studies using ambulatory blood pressure measurement for the management of antihypertensive treatment are scarce. 16 In one study, less intensive antihypertensive drug treatment was observed with the use of 24-h blood pressure measurement, whereas overall blood pressure con-trol was maintained in both treatment groups. 16 However, this trial included subjects with white coat hypertension, who were subsequently treated only in the office blood pressure group. Thus, the use of 24-h blood pressure measurement may even improve blood pressure control in individuals with elevation of both blood pressure values (that is, sustained hypertension). This would be highly desirable because of the high cardiovascular risk in these individuals. 12, 17, 18 We therefore designed the present study to compare 24-h ambulatory blood pressure to standard office blood pressure in the management of antihypertensive therapy in individuals with sustained hypertension.
Materials and methods

Patient population
Men and women aged 18 years or older were eligible for enrollment if they had a mean of two office blood pressure measurements of at least 140 mm Hg for systolic or 90 mm Hg for diastolic blood pressure. Increased office blood pressure had to be confirmed by a second set of measurements on another day. Participants were eligible for randomization if they had sustained hypertension, that is, if their systolic or diastolic 24-h blood pressure was X130 or X80 mm Hg, respectively. Exclusion criteria were a history of severe cardiovascular or cerebrovascular disease, an acute myocardial infarction, stroke or revascularization procedure within 6 months, or any other severe concomitant illness (for example, congestive heart failure or malignant cancer). Prevalent diabetes was not an exclusion criterion. The institutional review board of the University Hospital in Basel approved the study protocol and all participants provided written informed consent.
Procedures
This was a randomized, controlled, open-label parallel-group study from two medical centres in Switzerland (one medical outpatient clinic and one primary care practice). Consecutive patients with elevated office blood pressure on a screening visit were invited for a second visit to confirm elevated office blood pressure and perform 24-h blood pressure measurement. Eligible patients were then randomly assigned in a 1:1 ratio to a strategy using 24-h blood pressure to manage antihypertensive treatment (target o130 mm Hg for systolic and o80 mm Hg for diastolic blood pressure) or to a standard strategy using office blood pressure (target o140 mm Hg for systolic and o90 mm Hg for diastolic blood pressure). Treating physicians were then informed about the group assignment of each patient and instructed to adjust antihypertensive therapy at each measurement occasion according to the target blood pressure of the treatment group a specific patient was allocated to, and by ignoring blood pressure values obtained from the other measurement technique. Adherence to this treatment schedule was supervised by an independent physician and no protocol violation was detected. We believed that blinding of the physician would be very difficult to achieve, especially with regard to office blood pressure measurements, and we therefore decided to perform an open-label study. The randomization sequence was computer-generated and kept by one of the authors who was not involved in patient care. Physicians involved in patient care were unaware of the assignment sequence. Randomization was stratified by previously known versus previously unknown hypertension.
Sitting office blood pressure was measured at the left arm after at least five minutes of rest using a validated oscillometric device with an appropriately sized cuff. 19 The 24-h blood pressure device was attached to the left arm. Only validated devices were used in this study (Mobil-O-Graph; IEM, Stolberg, Germany; or Spacelabs 90207; SpaceLabs Medical Inc., Redmond, Washington, USA). 20, 21 Blood pressure was measured every 20 min between 8am and 10pm, and every 30 min between 10 pm and 8 am. Participants were told to engage in their usual activities during the measurement period, but to keep their arm still during recordings. Mean 24-h blood pressure was calculated using an unweighted average of all individual blood pressure values. All 24-h blood pressure profiles remained unedited. Blood pressure measurements were performed at baseline, 1 month, 6 months and 1 year of follow-up. Both office and 24-h measurements were performed in all participants. Between visit blood pressure measurements were strongly discouraged.
Participants with untreated hypertension received telmisartan 80 mg as first-line treatment. If blood pressure remained uncontrolled at the next visit, low-dose hydrochlorothiazide (12.5 mg) was added. If blood pressure was still above target, nifedipine CR 20 mg was added as third-line therapy. In patients with known hypertension, optimization of the established blood pressure-lowering treatment was recommended before starting a new drug. If a new drug was to be added, the same steps as in previously untreated participants were suggested, if there was no overlap with pre-existing therapy. Advice on lifestyle changes was given to each participant according to current guidelines. 1 
End points
The pre-specified primary end point of this study was a change in the 24-h systolic blood pressure from baseline to 1 year of follow-up. Pre-specified secondary end points were the change in 24-h diastolic blood pressure from baseline to 1 year of follow-up, changes in systolic and diastolic office blood pressure from baseline to 1 year of follow-up, and the proportion of participants with controlled 24-h or office blood pressure levels at 1 year. Adverse events were reported by the participating physicians and defined as any cardiovascular event or any event potentially related to a study drug.
Statistical analysis
All analyses were performed according to a prespecified analysis plan. Assuming a two-sided a of 0.05, a s.d. of 11 mm Hg and a drop-out rate of 5%, a total of 168 participants, 84 in each arm, needed to be randomized to give the study a power of 80% to detect a between group difference of 5 mm Hg. All participants reaching at least 6 months of follow-up were included in the primary analysis. We used the last value carried forward principle to substitute missing values at the final visit.
Baseline characteristics according to the treatment group were compared using the Wilcoxon rank sum test for continuous variables or the Fisher exact test for categorical variables. Changes in blood pressure from randomization to 1 year of follow-up were compared using analysis of covariance with baseline blood pressure and hypertension status as covariates. The model assumptions were checked by assessing the normality of the residuals, and no violations were detected.
For the primary end point, several pre-specified sensitivity analyses were performed. First, we analysed all participants with at least one followup blood pressure value. Given that no participants were lost between randomization and 1 month of follow-up, this analysis corresponds to an intentionto-treat analysis. Second, we included only participants who had a 24-h blood pressure measurement at the final visit after 1 year of follow-up.
The change in 24-h diastolic blood pressure from baseline to 1 year of follow-up and changes in systolic and diastolic office blood pressure from baseline to 1 year of follow-up were also compared using analysis of covariance with baseline blood pressure, and hypertension status included as covariates. The proportion of patients with controlled blood pressure (either office blood pressure o140 mm Hg for systolic and o90 mm Hg for diastolic blood pressure, or 24-h blood pressure o130 mm Hg for systolic and o80 mm Hg for diastolic blood pressure) was compared using a logistic regression model with baseline systolic blood pressure, diastolic blood pressure and hypertension status as covariates.
The number of antihypertensive drugs per participant at the final visit according to the treatment group was assessed using the Wilcoxon rank sum test. We also performed a pre-specified subgroup analysis in participants with previously known versus previously unknown hypertension. Changes in 24-h and office blood pressure from randomization to 1 year of follow-up were analysed separately in the two strata, using the same methods described above. We used SAS version 9 (SAS Institute Inc., Cary, NC, USA) for all statistical analyses. A two tailed P-value o0.05 indicated statistical significance.
Results
From the 238 individuals enrolled in the study, 165 were eligible and provided informed consent for randomization (Figure 1 ). Of these, 29 discontinued the study before the examination at 6 months and were subsequently not included in the main analyses. Baseline characteristics of the 136 included participants are shown in Table 1 . Mean age was 56 years and 46% had newly detected hypertension. There were no significant differences between the two treatment groups.
Baseline blood pressure values are shown in Table 2 . Although participants randomized to the ambulatory blood pressure group had lower systolic blood pressure values at baseline, these differences did not reach statistical significance (all between group P-values 40.20). During follow-up, there was a significant reduction in systolic 24-h blood pressure in both treatment groups (least square mean (95% confidence interval) À13.5 mm Hg (À15.8, À11.2 mm Hg) in the ambulatory blood pressure group, and À9.8 mm Hg (À12.3, À7.4 mm Hg) in the office blood pressure group) ( Table 2 and Figure 2 ). The reduction of systolic 24-h blood pressure was 3.6 mm Hg greater in the ambulatory blood pressure group than in the office blood pressure group (95% confidence interval 0.3, 7.0 mm Hg; P ¼ 0.03). The between group difference was similar for systolic office blood pressure, although it did not reach statistical significance (P ¼ 0.12). Diastolic blood pressure was reduced to a similar degree in both groups.
Sensitivity analyses for the primary end point showed comparable results. Among the 165 partici- pants included in the intention-to-treat analysis, the reduction in 24-h systolic blood pressure was greater in the ambulatory blood pressure group (difference in change compared with the office blood pressure group À2.8 mm Hg (À5.9, 0.2 mm Hg; P ¼ 0.06)). Restricting the analysis to the 119 participants who had a valid 24-h blood pressure measurement at the 1-year visit showed a reduction of À5.0 mm Hg (À8.2, 1.8 mm Hg; P ¼ 0.003) in favour of the ambulatory blood pressure group. Subgroup analysis revealed that the benefit of ambulatory blood pressure guided treatment was evident only in the group with previously known hypertension ( Table 3) . The blood pressure reduction was similar in both groups among participants with newly detected hypertension at baseline. On the other hand, in participants with previously known hypertension who were randomized to the ambulatory blood pressure group, the reduction of 24-h systolic and diastolic blood pressure was 7.2 mm Hg (11.6, 2.8 mm Hg) and 3.4 mm Hg (6.0, 0.9 mm Hg) greater compared with those randomized to the office blood pressure group. Although the differences in office blood pressure reduction were very similar to the differences in 24-h blood pressure reduction, they did not reach Antihypertensive therapy according to drug class and treatment group is shown in Table 4 . As recommended in the study protocol, the use of angiotensin receptor blockers and diuretics increased substantially during follow-up. Furthermore, the use of all major antihypertensive drug classes increased in both treatment groups. At 1 year of follow-up, the mean number of antihypertensive drugs taken was 1.76 ± 1.1 in the ambulatory blood pressure group and 1.95 ± 0.9 in the office blood pressure group (P for difference ¼ 0.049). The proportion of participants with controlled 24-h blood pressure was significantly greater in the ambulatory blood pressure group compared with the office blood pressure group (60 versus 42%, P ¼ 0.04). Control rates for office blood pressure were not significantly different between the two groups (41% in the ambulatory blood pressure group versus 35% in the office blood pressure group, P ¼ 0.4). Major adverse events are shown in Table 5 . 
Abbreviations: ACE, angiotensin converting enzyme; BP, blood pressure. 
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Discussion
This study indicates that the use of 24-h blood pressure measurement in individuals with sustained hypertension leads to significantly greater reductions in systolic 24-h blood pressure compared with a standard strategy using office blood pressure measurement, a benefit seen mainly in participants with previously known hypertension. Our findings are in line with previous studies. The use of 24-h blood pressure to manage antihypertensive therapy in subjects with office hypertension was previously associated with less intensive antihypertensive drug treatment, whereas overall blood pressure levels were similar in both treatment groups. 16 The present study confirms and expands these findings. Excluding subjects with white coat hypertension who are at low cardiovascular risk allowed us to directly compare ambulatory and office blood pressure measurement. Our data show that the use of 24-h blood pressure leads to better blood pressure control in subjects with sustained hypertension. This improvement was achieved despite the fact that the mean number of antihypertensive drugs was lower in the ambulatory blood pressure group, suggesting that blood pressure reduction can be achieved more efficiently by this technique. Another study provides indirect support for the more widespread use of 24-h blood pressure measurement, by showing that blood pressure response to antihypertensive treatment may vary considerably depending on the measurement technique used. 22 Patients with white coat hypertension had a high rate of 24-h blood pressure non-response, suggesting that the use of ambulatory blood pressure measurement may identify a subgroup of patients who do not benefit from antihypertensive treatment.
Home blood pressure measurement is potentially cheaper than 24-h blood pressure measurement, and might therefore be the preferred ambulatory blood pressure measurement technique. However, although the use of home blood pressure may also reduce the intensity of drug treatment, it is unclear whether 24-h blood pressure control rates can be maintained. 23 Again using a high home blood pressure treatment target of 140 mm Hg for systolic and 90 mm Hg for diastolic blood pressure, Verberk et al. 24 recently confirmed in a study of 430 participants with office hypertension that home blood pressure guided treatment may lead to less medication use, but this study also found significantly elevated 24-h blood pressure levels in the home blood pressure group. On the other hand, a small study among 98 participants with daytime ambulatory blood pressure of at least 85 mm Hg found similar blood pressure control rates whether antihypertensive therapy was adjusted based on home or 24-h blood pressure measurement. 25 Treatment target in this study was a diastolic blood pressure of 80 mm Hg in both groups. Thus, this study suggests that home blood pressure measurement may be a suitable alternative if a correct blood pressure target is chosen, but more studies are needed before home blood pressure can be recommended for antihypertensive treatment titration. Finally, it has to be emphasized that in contrast to home blood pressure measurement, 24-h blood pressure measurement can give additional important information about night-time blood pressure, 9 dipping status [26] [27] [28] or 24-h blood pressure variability, 13 all of which may lead to improved risk stratification of individuals with hypertension. On the other hand, potential drawbacks of 24-h blood pressure measurement include additional costs and patient discomfort.
Meta-analyses of previous randomized and observational studies have demonstrated that a systolic blood pressure reduction of 4 mm Hg could translate in a 23% reduction of stroke and a 15% reduction of major cardiovascular events. 29, 30 Thus, if confirmed by other studies, these potential benefits should outweigh the increased burden of regular 24-h blood pressure measurements for the individual hypertensive subject. Even more longterm benefits may eventually be expected, because the number of drugs an individual is taking per day is an important predictor of adherence to antihypertensive therapy. 31 Interestingly, the benefits of 24-h blood pressure measurement in this study seem to be limited to individuals with previously known hypertension. The reason for this observation is unclear. A plausible hypothesis would be that individuals with newly diagnosed hypertension are less adherent than those who already used antihypertensive therapy before the study. Accordingly, those with newly detected hypertension might not yet be willing to comply with a more complex intervention scheme. Our analysis showing less reduction of 24-h blood pressure in subjects with newly detected hypertension supports this hypothesis.
The treatment threshold for 24-h blood pressure measurement (130 mm Hg for systolic and 80 mm Hg for diastolic blood pressure) certainly influenced our results. We based our decision on a classification proposed at the Eighth International Consensus Conference on Ambulatory Blood Pressure Measurement in 2001. 32 It has been shown recently that a 24-h blood pressure and antihypertensive treatment D Conen et al population-based outcome-driven threshold for hypertension exactly corresponds to the one chosen in this study, 33 confirming the validity of this threshold.
This study should be evaluated in the context of its limitations. Although adequately powered to detect a meaningful blood pressure difference between the treatment groups, the study was not large and long enough to detect differences in cardiovascular outcomes. Participants of this study were not blinded. The present study was performed among individuals with sustained hypertension using 24-h blood pressure measurement, and the results should not be extrapolated to other populations or measurement techniques. Although we have exact information on the number of antihypertensive drugs, the corresponding doses were not collected. Finally, the drop-out rate was considerable ( Figure 1 ). This may be explained by the complexity of the intervention and the substantial number of newly detected hypertensives included in the study. Given the consistent findings in the intention-to-treat analysis, we are confident that the results of this study are valid.
Conclusion
Among individuals with sustained hypertension, a strategy using 24-h blood pressure measurement in the management of antihypertensive therapy leads to greater reductions in 24-h systolic blood pressure and increased control rates of ambulatory hypertension. These benefits were mainly evident among individuals with previously known hypertension. Our results provide a strong rationale to pursue the testing of a 24-h blood pressure-based treatment strategy in large cardiovascular outcome trials.
